MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We h...

Descripción completa

Detalles Bibliográficos
Autores principales: Obata, Shota, Hidaka, Sumi, Yamano, Mizuki, Yanai, Mitsuru, Ishioka, Kunihiro, Kobayashi, Shuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Exceptional Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500057/
https://www.ncbi.nlm.nih.gov/pubmed/35140936
http://dx.doi.org/10.1093/ckj/sfab181
_version_ 1784580383646416896
author Obata, Shota
Hidaka, Sumi
Yamano, Mizuki
Yanai, Mitsuru
Ishioka, Kunihiro
Kobayashi, Shuzo
author_facet Obata, Shota
Hidaka, Sumi
Yamano, Mizuki
Yanai, Mitsuru
Ishioka, Kunihiro
Kobayashi, Shuzo
author_sort Obata, Shota
collection PubMed
description Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.
format Online
Article
Text
id pubmed-8500057
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85000572021-10-08 MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination Obata, Shota Hidaka, Sumi Yamano, Mizuki Yanai, Mitsuru Ishioka, Kunihiro Kobayashi, Shuzo Clin Kidney J Exceptional Case Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect. Oxford University Press 2021-09-28 /pmc/articles/PMC8500057/ /pubmed/35140936 http://dx.doi.org/10.1093/ckj/sfab181 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Exceptional Case
Obata, Shota
Hidaka, Sumi
Yamano, Mizuki
Yanai, Mitsuru
Ishioka, Kunihiro
Kobayashi, Shuzo
MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
title MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
title_full MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
title_fullStr MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
title_full_unstemmed MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
title_short MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
title_sort mpo-anca-associated vasculitis after the pfizer/biontech sars-cov-2 vaccination
topic Exceptional Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500057/
https://www.ncbi.nlm.nih.gov/pubmed/35140936
http://dx.doi.org/10.1093/ckj/sfab181
work_keys_str_mv AT obatashota mpoancaassociatedvasculitisafterthepfizerbiontechsarscov2vaccination
AT hidakasumi mpoancaassociatedvasculitisafterthepfizerbiontechsarscov2vaccination
AT yamanomizuki mpoancaassociatedvasculitisafterthepfizerbiontechsarscov2vaccination
AT yanaimitsuru mpoancaassociatedvasculitisafterthepfizerbiontechsarscov2vaccination
AT ishiokakunihiro mpoancaassociatedvasculitisafterthepfizerbiontechsarscov2vaccination
AT kobayashishuzo mpoancaassociatedvasculitisafterthepfizerbiontechsarscov2vaccination

Ejemplares similares